Palvella director reports fully vested stock option
PALVELLA THERAPEUTICS, INC. director John Doux filed an initial ownership report showing a stock option holding.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
PALVELLA THERAPEUTICS, INC. director John Doux filed an initial ownership report showing a stock option holding. The filing lists a fully vested stock option to acquire 10,364 shares of common stock at an exercise price of $7.14 per share, expiring on February 4, 2030.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Footnotes (1)
- F1. The stock option is fully vested.
Key Figures
Key Terms
Stock Option (Right to Buy) financial
Common Stock financial
fully vested financial
exercise price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider position did John Doux report at PALVELLA THERAPEUTICS (PVLA)?
What is the exercise price of John Doux’s PALVELLA THERAPEUTICS stock option?
When does John Doux’s PALVELLA THERAPEUTICS stock option expire?
Is John Doux’s PALVELLA THERAPEUTICS stock option currently vested?
AI-generated analysis. How Rhea-AI works. Not financial advice.